Edition:
United States

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

1,725JPY
23 May 2017
Change (% chg)

¥-6 (-0.35%)
Prev Close
¥1,731
Open
¥1,730
Day's High
¥1,746
Day's Low
¥1,723
Volume
997,500
Avg. Vol
1,135,018
52-wk High
¥2,134
52-wk Low
¥1,520

Latest Key Developments (Source: Significant Developments)

Sumitomo Dainippon Pharma revises consolidated mid-year and full-year outlook for FY 2016
Wednesday, 29 Jul 2015 02:00am EDT 

Sumitomo Dainippon Pharma Co., Ltd:Says the company increased the consolidated mid-year outlook for revenue to 197.5 billion yen from 193 million yen for FY ending March 2016.Operating profit forecast remained at 11 billion yen.Ordinary profit forecast remained at 11 billion yen.Net profit forecast remained at 8 billion yen.Says the company increased the consolidated full-year outlook for revenue to 401 billion yen from 392 million yen for FY ending March 2016.Operating profit forecast remained at 27 billion yen.Ordinary profit forecast remained at 26.5 billion yen.Net profit forecast remained at 18 billion yen.  Full Article

R&I affirms Sumitomo Dainippon Pharma's rating at "A" and announces stable outlook
Thursday, 16 Jul 2015 02:00am EDT 

Sumitomo Dainippon Pharma Co., Ltd:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A".Rating outlook stable.  Full Article

Sumitomo Dainippon Pharma and JCR Pharmaceuticals conclude a feasibility study agreement on application of the blood-brain barrier penetration technology in psychiatry and neurology area
Wednesday, 17 Jun 2015 03:00am EDT 

Sumitomo Dainippon Pharma Co., Ltd and JCR Pharmaceuticals Co Ltd:JCR Pharmaceuticals (“JCR”) and Sumitomo Dainippon Pharma executed on June 17 a feasibility study agreement.Under which they will study the feasibility of applying JCR’s proprietary blood-brain barrier penetration technology “J-Brain Cargo” to discovery of new treatment in the psychiatry and neurology area.Under the terms of the agreement, JCR and Sumitomo Dainippon Pharma will perform collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Sumitomo Dainippon Pharma’s choice.With a view to creating innovative pharmaceutical products in psychiatry and neurology area, where high unmet medical needs exist.  Full Article

More From Around the Web

BRIEF-Sumitomo Dainippon Pharma looks to expand applications of drug candidate Dasotraline - Nikkei

* Sumitomo Dainippon Pharma Co Ltd looks to expand the applications of its drug candidate dasotraline - Nikkei